NASDAQ · Medical - Diagnostics & Research

IMDX (IMDX) Stock

$3.84 -2.04% NASDAQ: IMDX Healthcare

Valuation

MetricValue
Price$3.84
Market Cap$123.99M
P/E Ratio-2.83
P/B Ratio-7.42
P/S Ratio83.14
EPS (TTM)$-1.65
52-Week High$8.51
52-Week Low$2.33
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE271.76%
ROA-167.64%
ROCE-223.06%
Gross Margin-775.00%
Operating Margin-775.00%
Net Margin-24.55%
Debt/Equity-0.12
Current Ratio1.25

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$1.0M$2.0M$2.0M$4.0M
Operating Profit$-54.0M$-18.0M$-25.0M$-61.0M$-31.0M
Net Profit$-64.0M$-73.0M$-28.0M$-61.0M$-50.0M
EPS$-14.40$-20.00$-3.75$-4.66$-1.65
Op Margin-2444.3%-1878.6%-1672.4%-3245.1%-754.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$160.0M$100.0M$75.0M$35.0M$26.0M
Total Liabilities$94.0M$60.0M$54.0M$47.0M$57.0M
Cash$33.0M$20.0M$9.0M$9.0M$12.0M
Borrowings$6.0M$4.0M$3.0M$4.0M$3.0M

Latest News

IMDx Chief Science Officer Ekkehard Schuetz Publishes 200th Research Paper GlobeNewswire · Jun 29, 2026 iMDx and the American Society of Transplant Surgeons Announce Recipients of the ASTS-iMDx Health Economics Research Grant GlobeNewswire · Jun 22, 2026 ​Breakthrough Science Meets Market Skepticism: Insight Molecular Diagnostics Inc. (IMDX)’s Defining Moment Insider Monkey · Jun 19, 2026 Favorable Head-to-Head Data on iMDx’s GraftAssure with Competing NGS Assay Published in Clinical Chemistry GlobeNewswire · Jun 16, 2026 IMDX GraftAssure Assay Sets New Standard in Screening Kidney Transplant Patients Per American Journal of Transplantation GlobeNewswire · Jun 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-36.0M$-46.0M$-23.0M$-21.0M$-22.0M
Investing Cash Flow$-16.0M$-9.0M$-1.0M$-1.0M$-6.0M
Financing Cash Flow$2.0M$0$0$-2.0M$0
Net Cash Flow$28.0M$-14.0M$-12.0M$-1.0M$4.0M
Free Cash Flow$-38.0M$-50.0M$-24.0M$-21.0M$-25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.03
EV / EBITDA-2.64
FCF Yield-22.24%
Quick Ratio1.98
Interest Coverage-436.03
Return 1Y57.04%
Return 3Y2.76%
Return 5Y-95.85%

Ownership

Insiders Held21.28%
Institutions Held60.78%
Institutions Float Held77.22%
Institutional HolderSharesReport Date
Broadwood Capital, Inc.11,931,8392026-03-31
AWM Investment Company, Inc.2,806,2562026-03-31
Pura Vida Investments, Llc947,1342026-03-31
Alyeska Investment Group, L.p.840,7772026-03-31
Vanguard Capital Management LLC537,1612026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ARMP $5.28 -4.17% -1.03 $193.83M 0.00%
CCCC $3.87 +4.31% -2.54 $427.89M 0.00%
CDXS $1.51 -11.18% -5.06 $162.42M 0.00%
CYBNCybin Inc. $8.28 +1.22% -1.67 $413.02M 0.00%
IVVD $0.88 -7.85% -3.53 $259.22M 0.00%

About IMDX

IMDX is led by CEO Joshua Riggs, employs 46 people, headquartered in US, publicly traded since 2015.

IMDX stock trades at $3.84 with a market capitalization of $123.99M. The stock is valued at a price-to-earnings (P/E) ratio of -2.83, price-to-book of -7.42, price-to-sales of 83.14. Over the past 52 weeks the stock has ranged between $2.33 and $8.51, and currently trades 54.9% below its 52-week high.

On profitability, IMDX generates a return on equity (ROE) of 271.76% — well above the market average, a sign of a high-quality business, return on capital employed of -223.06%, an operating margin of -775.00%, a net profit margin of -24.55%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1159.93 +0.28% JNJ Drug Manufacturers - General $271.19 +2.01% ABBV Drug Manufacturers - General $259.99 +1.39% MRK Drug Manufacturers - General $149.94 +1.48% UNH Medical - Healthcare Plans $396.30 +1.77% NVS Drug Manufacturers - General $161.25 +6.04% AZN Drug Manufacturers - General $162.47 +0.21% AMGN Drug Manufacturers - General $438.12 +1.92% TMO Medical - Diagnostics & Research $600.50 -2.69% NVO Biotechnology $45.12 -0.46% ABT Medical - Devices $108.97 -1.26% GILD Drug Manufacturers - General $149.92 +2.45%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides